Tracer library / [89Zr]trastuzumab-PEG6-DM1

[89Zr]trastuzumab-PEG6-DM1

Also written as [Zr-89]Zr-trastuzumab-PEG6-DM1

Radionuclide: Zr-89 t½ 4704 min
Modality: PET
Production route: —
Stage: Reported once
Syntheses indexed: 0

Breast cancer

What it is

Compound class: Antibody-drug conjugate (trastuzumab-PEG6-DM1, HER2-targeting)
Target / mechanism: HER2 (domain IV targeting antibody-drug conjugate) PMID 37095184
Clinical application: Breast cancer theranostics (biparatopic anti-HER2 drug radioconjugates) PMID 37095184
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [89Zr]trastuzumab-PEG6-DM1, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37095184. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37095184: 'trastuzumab-PEG6-DM1 (domain IV) and pertuzumab-PEG6-DM1 (domain II) were developed, characterised and radiolabeled to obtain [89Zr]Zr-trastuzumab-PEG6-DM1'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Zr-89 is a positron emitter used only for PET imaging. Linked articles: PMID 37095184.